Rooted Medication
Forbes Indonesia|August 2019

Nalagenetics, paving the way for safer healthcare industry.

Marella Putri
Rooted Medication

When guideline-prescribed drugs don’t work on a patient or cause even worse symptoms, the patient is probably enduring an adverse drug reaction (ADR). Usually, the doctor will simply treat the patient on the basis of clinical trial and error, despite not everyone being able to accept the same type of drugs. Often patients lose time and money and become vulnerable to other types of reaction. In the US, ADR is the fourth major cause of death, causing 8% of hospital admissions and losses of up to $60 billion.

Between 30% and 70% of ADR cases are related to a patient’s genetic response.

Therefore, a Singapore-based medtech startup, Nalagenetics is promoting a solution through pharmacogenomics—the study of genetic responses to drugs that can reduce the risk of an ADR. By analyzing a patient’s genetics, Nalagenetics will be able to recommend to doctors how their patients would respond to certain types of drugs and advise the safe dosage to prevent an ADR. Thus, the startup aims to reduce cases of ADR while increasing the effectiveness of prescribed dosages.

Nalagenetics was cofounded by a team of scientists who met at the Genome Institute of Singapore. The startup initially was meant only to work on a non-profit project on leprosy in Papua, Indonesia—and not become the established company Nalagenetics is now. The team worked with Indonesia’s Research and Development Body (Litbangkes) at the Ministry of Health, and an NGO called Leprosy Research Initiative back in 2016. They sampled the DNA of the patients and analyzed whether their genetics were suited to treatment with WHO-certified leprosy drug Dapsone, given that its worst adverse reaction could have fatal consequences.

This story is from the {{IssueName}} edition of {{MagazineName}}.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

This story is from the {{IssueName}} edition of {{MagazineName}}.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

MORE STORIES FROM FORBES INDONESIAView all
BACK ON TRACK
Forbes Indonesia

BACK ON TRACK

Collective wealth gets a 21% boost to a record $162 billion amid an economic uptick.

time-read
10+ mins  |
December 2021
Championing Locals
Forbes Indonesia

Championing Locals

The wave of social commerce is enabling inclusive digital economies beyond urban areas.

time-read
6 mins  |
December 2021
Boys in the Bubble
Forbes Indonesia

Boys in the Bubble

Startups are supposed to specialize, but OPENSEA’s founders thrived by building a wide-open market for creating and trading all manner of NFTs, whether art, music or gaming. Now that they’re centimillionaires and poised to become billionaires, they have other worries: competitors, fraudsters and the next crypto crash.

time-read
6 mins  |
December 2021
Enduring Relations
Forbes Indonesia

Enduring Relations

The implementation of IA-CEPA amid the pandemic signifies the Indonesia-Australia’s commitment to recover and counter future challenges together.

time-read
6 mins  |
December 2021
Sweet Success
Forbes Indonesia

Sweet Success

Steven Erwin envisions Unifam to become a major global player in the confectionery and F&B industry.

time-read
5 mins  |
December 2021
Marathon Man
Forbes Indonesia

Marathon Man

Across America, scores of municipal pension funds remain scandalously underfunded. But not the pension fund of Tampa’s police and firemen, thanks in large part to JAY BOWEN, whose no-frills approach to stock picking has protected and served them for more than 45 years.

time-read
5 mins  |
December 2021
Gold Rallies on Inflation Fears
Forbes Indonesia

Gold Rallies on Inflation Fears

During September the price of gold rallied to $1,868 per ounce following the release of figures on US inflation by the Bureau of Labor Statistics which indicated that, as of September, CPI inflation had rocketed to 6.2%, above the 5.8% which economists had been predicting.

time-read
2 mins  |
December 2021
Set Off to A New Start
Forbes Indonesia

Set Off to A New Start

Bank Aladin has two main ingredients for success: establish trust and offer better customer experiences.

time-read
5 mins  |
December 2021
The Daily Intake
Forbes Indonesia

The Daily Intake

YOUVIT plans to invest further into marketing and grow into one of the leading vitamin brands in Indonesia.

time-read
4 mins  |
December 2021
THE CROESUS OF CRYPTO
Forbes Indonesia

THE CROESUS OF CRYPTO

FTX COFOUNDER SAM BANKMAN-FRIED BUILT A $22.5 BILLION FORTUNE BEFORE HIS 30TH BIRTHDAY BY PROFITING OFF THE CRYPTOCURRENCY FRENZY—BUT HE’S NOT A TRUE BELIEVER. HE JUST WANTS HIS WEALTH TO SURVIVE LONG ENOUGH TO GIVE IT ALL AWAY.

time-read
10+ mins  |
November 2021